Sinnollareddy, Mahipal
Sousa, Eduardo
Soy Muner, Dolors
Spring, Anna
Starr, Therese
Stephens, Dianne
Taccone, Fabio Silvio
Thomas, Jane
Turnidge, John
Valkonen, Miia
De Waele, Jan J.
Varghese, Julie M.
Deans, Renae
Wallis, Steven C.
Donnellan, Sine
Walker, Robert J.
Eastwood, Glenn M.
Williams, Tricia
Frey, Otto R.
Wilson, Luke C.
Goutelle, Sylvain
Wittebole, Xavier
Gresham, Rebecca
Ain Jamal, Janattul
Joynt, Gavin M.
Kanji, Salmaan
Roberts, Jason A.
Ulldemolins, Marta
Liu, Xin
Baptista, João P.
Bilgrami, Irma
Boidin, Clement
Brinkmann, Alexander
Castro, Pedro
Choi, Gordon
Cole, Louise
Wright, Daniel F.B.
Zikou, Xanthi T.
Bellomo, Rinaldo
Lipman, Jeffrey
Kluge, Stefan
König, Christina
Koulouras, Vasilios P.
Lassig-Smith, Melissa
Laterre, Pierre-Francois
Lee, Anna
Lefrant, Jean-Yves
Lei, Katie
Leung, Patricia
Llauradó Serra, Mireia
Martín Loeches, Ignacio
Mat Nor, Mohd Basri
Mudaliar, Yugan
Ostermann, Marlies
Paul, Sanjoy K.
Peake, Sandra L.
Rello, Jordi
Roberts, Darren M.
Roberts, Michael S.
Richards, Brent
Rodríguez, Alejandro
Roehr, Anka C.
Roger, Claire
Seoane, Leonardo
2025-12-03T16:43:52Z
2025-12-03T16:43:52Z
2025-08-13
2025-12-03T16:43:52Z
Purpose: Optimal dosing of meropenem and piperacillin/tazobactam in critically ill patients receiving renal replacement therapy (RRT) is uncertain due to variable pharmacokinetics. We aimed to develop generalisable optimised dosing recommendations for these antibiotics. Methods: Prospective, multinational pharmacokinetic study including patients requiring various forms of RRT. Independent population PK models were developed, externally validated and applied to perform Monte Carlo dosing simulations using Monolix and Simulx. We calculated the probability that these dosing regimens achieved standard and high therapeutic unbound antibiotic concentrations over 100% of the dosing interval for the treatment of Enterobacterales and Pseudomonas aeruginosa. Results: We enrolled 300 patients from 22 intensive care units across 12 countries receiving continuous veno-venous haemodialysis (13.0%), haemofiltration (23.3%), haemodiafiltration (48.4%) or sustained low-efficiency dialysis (15.3%). Models were developed using data from 234 patients (8322 samples) and validated with 66 additional patients (560 samples). Predictive performance was high, with mean prediction errors of - 5.2% for meropenem and - 16.9% for piperacillin. Dosing simulations showed that meropenem and piperacillin/tazobactam dosing requirements were dependent on urine output and RRT intensity and duration (p < 0.05). In all scenarios, extended/continuous infusions led to a better achievement of effective concentrations with lower daily doses compared to short infusion. Dosing nomograms were developed to inform dosing for different RRT settings, urine outputs, and target concentrations. Conclusion: RRT intensity and duration and urine output determine meropenem and piperacillin/tazobactam dosing requirements in critically ill patients receiving RRT. Extended/continuous infusions facilitate the attainment of effective concentrations.
English
Unitats de cures intensives; Malalts en estat crític; Medicaments antibacterians; Intensive care units; Critically ill; Antibacterial agents
Springer Verlag
Reproducció del document publicat a: https://doi.org/10.1007/s00134-025-08067-w
Intensive Care Medicine, 2025, vol. 51, num.9, p. 1628-1640
https://doi.org/10.1007/s00134-025-08067-w
cc by-nc (c) Sinnollareddy, Mahipal et al., 2025
https://creativecommons.org/licenses/by-nc/4.0/